STAT3 and pulmonary arterial hypertension: Therefore, we hypothesized that the long-term efficacy of combination therapies using AAV1.hSERCA2a with AAV1.BMPR2 or a STAT3 inhibitor (STAT3i, HJC0152) might reverse serious respiratory and hemodynamic alterations as well as RV remodeling while restoring RV function in a severe PAH rat model.